HRP20140807T1 - Derivati pirolo[2,3-d]pirimidina kao inhibitori protein kinaze b - Google Patents
Derivati pirolo[2,3-d]pirimidina kao inhibitori protein kinaze b Download PDFInfo
- Publication number
- HRP20140807T1 HRP20140807T1 HRP20140807AT HRP20140807T HRP20140807T1 HR P20140807 T1 HRP20140807 T1 HR P20140807T1 HR P20140807A T HRP20140807A T HR P20140807AT HR P20140807 T HRP20140807 T HR P20140807T HR P20140807 T1 HRP20140807 T1 HR P20140807T1
- Authority
- HR
- Croatia
- Prior art keywords
- cancer
- pharmaceutically acceptable
- acceptable salt
- compound according
- treatment
- Prior art date
Links
- JJTNLWSCFYERCK-UHFFFAOYSA-N 7h-pyrrolo[2,3-d]pyrimidine Chemical class N1=CN=C2NC=CC2=C1 JJTNLWSCFYERCK-UHFFFAOYSA-N 0.000 title 1
- 239000003197 protein kinase B inhibitor Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims 17
- 150000003839 salts Chemical class 0.000 claims 13
- 206010028980 Neoplasm Diseases 0.000 claims 9
- 201000011510 cancer Diseases 0.000 claims 9
- 206010006187 Breast cancer Diseases 0.000 claims 6
- 208000026310 Breast neoplasm Diseases 0.000 claims 6
- 238000000034 method Methods 0.000 claims 6
- 239000003814 drug Substances 0.000 claims 4
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 3
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims 3
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 3
- 206010060862 Prostate cancer Diseases 0.000 claims 3
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 3
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 3
- 206010017758 gastric cancer Diseases 0.000 claims 3
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims 3
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims 3
- 201000005202 lung cancer Diseases 0.000 claims 3
- 208000020816 lung neoplasm Diseases 0.000 claims 3
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 3
- 201000002528 pancreatic cancer Diseases 0.000 claims 3
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 3
- 201000011549 stomach cancer Diseases 0.000 claims 3
- JDUBGYFRJFOXQC-KRWDZBQOSA-N 4-amino-n-[(1s)-1-(4-chlorophenyl)-3-hydroxypropyl]-1-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)piperidine-4-carboxamide Chemical compound C1([C@H](CCO)NC(=O)C2(CCN(CC2)C=2C=3C=CNC=3N=CN=2)N)=CC=C(Cl)C=C1 JDUBGYFRJFOXQC-KRWDZBQOSA-N 0.000 claims 2
- ZRDYBUCARNESOB-ZDUSSCGKSA-N 4-amino-n-[(1s)-1-(4-chlorophenyl)-3-hydroxypropyl]piperidine-4-carboxamide Chemical compound N([C@@H](CCO)C=1C=CC(Cl)=CC=1)C(=O)C1(N)CCNCC1 ZRDYBUCARNESOB-ZDUSSCGKSA-N 0.000 claims 2
- 230000015572 biosynthetic process Effects 0.000 claims 2
- 229940079593 drug Drugs 0.000 claims 2
- 125000006239 protecting group Chemical group 0.000 claims 2
- JGNACDMQJLVKIU-VIFPVBQESA-N (3s)-3-amino-3-(4-chlorophenyl)propan-1-ol Chemical compound OCC[C@H](N)C1=CC=C(Cl)C=C1 JGNACDMQJLVKIU-VIFPVBQESA-N 0.000 claims 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 125000002618 bicyclic heterocycle group Chemical group 0.000 claims 1
- 229910052801 chlorine Inorganic materials 0.000 claims 1
- 239000000460 chlorine Substances 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- QIGUQECRLHBCDL-FQEVSTJZSA-N tert-butyl n-[4-[[(1s)-1-(4-chlorophenyl)-3-hydroxypropyl]carbamoyl]-1-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)piperidin-4-yl]carbamate Chemical compound C1([C@H](CCO)NC(=O)C2(CCN(CC2)C=2C=3C=CNC=3N=CN=2)NC(=O)OC(C)(C)C)=CC=C(Cl)C=C1 QIGUQECRLHBCDL-FQEVSTJZSA-N 0.000 claims 1
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
- C07D473/32—Nitrogen atom
- C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Claims (19)
1. Spoj naznačen time da je: (S)-4-amino-N-(1-(4-klorofenil)-3-hidroksipropil)-1-(7H-pirolo[2,3-d]pirimidin-4-il)piperidin-4-karboksamid:
[image]
ili njegova farmaceutski prihvatljiva sol.
2. Farmaceutski pripravak naznačen time da sadrži spoj prema zahtjevu 1, ili njegovu farmaceutski prihvatljivu sol, zajedno s farmaceutski prihvatljivim razrjeđivačem ili nosačem.
3. Spoj prema zahtjevu 1, ili njegova farmaceutski prihvatljiva sol, naznačen time da je za uporabu kao lijek.
4. Spoj prema zahtjevu 1, ili njegova farmaceutski prihvatljiva sol, naznačen time da je za uporabu za liječenje raka.
5. Spoj prema zahtjevu 1, ili njegova farmaceutski prihvatljiva sol, naznačen time da je za uporabu za liječenje raka, gdje je rak odabran od raka dojke, ne-Hodgkinovog limfoma, raka gušterače, hepatocelularnog karcinoma, raka želuca, raka prostate i raka pluća.
6. Spoj prema zahtjevu 1, ili njegova farmaceutski prihvatljiva sol, naznačen time da je za uporabu za liječenje raka dojke.
7. Uporaba spoja prema zahtjevu 1, ili njegove farmaceutski prihvatljive soli, naznačena time da je za pripravu lijeka za liječenje raka.
8. Uporaba spoja prema zahtjevu 1, ili njegove farmaceutski prihvatljive soli, naznačena time da je za pripravu lijeka za liječenje raka, gdje je rak odabran od raka dojke, ne-Hodgkinovog limfoma, raka gušterače, hepatocelularnog karcinoma, raka želuca, raka prostate i raka pluća.
9. Uporaba spoja prema zahtjevu 1, ili njegove farmaceutski prihvatljive soli, naznačena time da je za pripravu lijeka za liječenje raka dojke.
10. Spoj: (S)-4-amino-N-(1-(4-klorofenil)-3-hidroksipropil)-1-(7H-pirolo[2,3-d]pirimidin-4-il)piperidin-4-karboksamid, kako je zatraženo u zahtjevu 1.
11. Spoj prema zahtjevu 10 naznačen time da je za uporabu kod liječenja raka.
12. Spoj prema zahtjevu 10 naznačen time da je za uporabu kod liječenja raka gdje je rak odabran od raka dojke, ne-Hodgkinovog limfoma, raka gušterače, hepatocelularnog karcinoma, raka želuca, raka prostate i raka pluća.
13. Spoj prema zahtjevu 10 naznačen time da je za uporabu kod liječenja raka dojke.
14. Postupak za pripravu spoja prema zahtjevu 1, ili njegove farmaceutski prihvatljive soli, naznačen time da postupak sadrži reakciju kiseline Formule (II) i (S)-3-amino-3-(4-klorofenil)propan-1-ola:
[image]
pri čemu P1 predstavlja pogodnu zaštitnu skupinu; te nakon toga, ako je potrebno:
uklanjanje zaštitne skupine; i/ili
tvorbu njegove farmaceutski prihvatljive soli.
15. Postupak prema zahtjevu 14, naznačen time da P1 predstavlja tert-butoksikarbonil zaštitnu skupinu.
16. Spoj: (S)-tert-butil4-(1-(4-klorofenil)-3-hidroksipropilkarbamoil)-1-(7H-pirolo[2,3-d]pirimidin-4-il)piperidin-4-ilkarbamat:
[image]
17. Postupak za pripravu spoja prema zahtjevu 1, ili njegove farmaceutski prihvatljive soli, naznačen time da postupak sadrži reakciju (S)-4-amino-N-(1-(4-klorofenil)-3-hidroksipropil)piperidin-4-karboksamida sa bicikličkim heterociklom sa Formulom (V):
[image]
pri čemu L1 predstavlja pogodnu odlazeću skupinu; te nakon toga ako je potrebno, tvorbu njegove farmaceutski prihvatljive soli.
18. Postupak prema zahtjevu 17, naznačen time da L1 je klor.
19. Spoj: (S)-4-amino-N-(1-(4-klorofenil)-3-hidroksipropil)piperidin-4-karboksamid:
[image]
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US97919207P | 2007-10-11 | 2007-10-11 | |
US4786208P | 2008-04-25 | 2008-04-25 | |
PCT/GB2008/050925 WO2009047563A1 (en) | 2007-10-11 | 2008-10-09 | Pyrrolo [2, 3 -d] pyrimidin derivatives as protein kinase b inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
HRP20140807T1 true HRP20140807T1 (hr) | 2014-11-21 |
Family
ID=40251789
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HRP20140807AT HRP20140807T1 (hr) | 2007-10-11 | 2014-08-26 | Derivati pirolo[2,3-d]pirimidina kao inhibitori protein kinaze b |
Country Status (38)
Country | Link |
---|---|
US (8) | US8101623B2 (hr) |
EP (1) | EP2201012B1 (hr) |
JP (2) | JP4705695B2 (hr) |
KR (1) | KR101494734B1 (hr) |
CN (1) | CN101861321B (hr) |
AR (1) | AR068846A1 (hr) |
AU (1) | AU2008309383B2 (hr) |
BR (1) | BRPI0818533B8 (hr) |
CA (1) | CA2701057C (hr) |
CL (1) | CL2008003023A1 (hr) |
CO (1) | CO6270328A2 (hr) |
CR (1) | CR11359A (hr) |
CU (1) | CU23886B1 (hr) |
CY (1) | CY1116929T1 (hr) |
DK (1) | DK2201012T3 (hr) |
DO (1) | DOP2010000103A (hr) |
EA (1) | EA018512B1 (hr) |
ES (1) | ES2522365T3 (hr) |
GT (1) | GT201000082A (hr) |
HK (1) | HK1143154A1 (hr) |
HN (1) | HN2010000653A (hr) |
HR (1) | HRP20140807T1 (hr) |
IL (1) | IL204721A (hr) |
ME (1) | ME01999B (hr) |
MX (1) | MX2010003927A (hr) |
MY (1) | MY150059A (hr) |
NI (1) | NI201000050A (hr) |
NZ (1) | NZ585261A (hr) |
PE (2) | PE20130152A1 (hr) |
PL (1) | PL2201012T3 (hr) |
PT (1) | PT2201012E (hr) |
RS (1) | RS53552B1 (hr) |
SA (1) | SA08290625B1 (hr) |
SI (1) | SI2201012T1 (hr) |
TW (1) | TWI453021B (hr) |
UY (1) | UY31384A1 (hr) |
WO (1) | WO2009047563A1 (hr) |
ZA (1) | ZA201002318B (hr) |
Families Citing this family (38)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MY179032A (en) | 2004-10-25 | 2020-10-26 | Cancer Research Tech Ltd | Ortho-condensed pyridine and pyrimidine derivatives (e.g.purines) as protein kinase inhibitors |
JP5606734B2 (ja) | 2006-04-25 | 2014-10-15 | アステックス、セラピューティックス、リミテッド | 医薬化合物 |
US8673548B2 (en) * | 2006-08-10 | 2014-03-18 | Oncotherapy Science, Inc. | Genes and polypeptides relating to breast cancers |
ES2522365T3 (es) | 2007-10-11 | 2014-11-14 | Astrazeneca Ab | Derivados de pirrolo [2,3-D] pirimidina como inhibidores de proteína quinasas B |
WO2011002772A1 (en) * | 2009-06-29 | 2011-01-06 | Oncotherapy Science, Inc. | Imidazopyridine derivatives and pbk inhibitors containing the same |
GB201020161D0 (en) | 2010-11-26 | 2011-01-12 | Almac Discovery Ltd | Pharmaceutical compounds |
JP5927201B2 (ja) | 2010-12-16 | 2016-06-01 | カルチャン リミテッド | Ask1阻害ピロロピリミジン誘導体 |
JP6100700B2 (ja) | 2011-01-11 | 2017-03-22 | ノバルティス アーゲー | 組合せ |
PL2694056T3 (pl) | 2011-04-01 | 2020-03-31 | Astrazeneca Ab | Leczenie terapeutyczne |
AU2013205648B2 (en) * | 2011-11-30 | 2015-02-05 | Astrazeneca Ab | Combination treatment |
PL2785349T5 (pl) * | 2011-11-30 | 2023-01-30 | Astrazeneca Ab | Kombinacja do leczenia nowotworu |
AU2013204533B2 (en) * | 2012-04-17 | 2017-02-02 | Astrazeneca Ab | Crystalline forms |
WO2014114928A1 (en) | 2013-01-23 | 2014-07-31 | Astrazeneca Ab | Chemical compounds |
EP2815749A1 (en) | 2013-06-20 | 2014-12-24 | IP Gesellschaft für Management mbH | Solid form of 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione having specified X-ray diffraction pattern |
WO2015013579A1 (en) | 2013-07-26 | 2015-01-29 | Update Pharma Inc. | Compositions to improve the therapeutic benefit of bisantrene |
JP6295578B2 (ja) * | 2013-09-30 | 2018-03-20 | 凸版印刷株式会社 | 反応容器、核酸解析装置、および核酸解析方法 |
MX2016004267A (es) * | 2013-10-01 | 2016-07-08 | Novartis Ag | Combinacion. |
CR20200362A (es) | 2014-02-13 | 2020-10-26 | Incyte Corp | CICLOPROPILAMINA COMO INHIBIDORES DE LA LSD1 (Divisional 2016-0395) |
US9527835B2 (en) | 2014-02-13 | 2016-12-27 | Incyte Corporation | Cyclopropylamines as LSD1 inhibitors |
HUE046273T2 (hu) | 2014-02-13 | 2020-02-28 | Incyte Corp | Ciklopropilaminok mint LSD1 inhibitorok |
US9493442B2 (en) | 2014-02-13 | 2016-11-15 | Incyte Corporation | Cyclopropylamines as LSD1 inhibitors |
KR102518994B1 (ko) * | 2014-05-28 | 2023-04-05 | 아스트라제네카 아베 | Azd5363의 제조 방법 및 그에 사용되는 신규 중간체 |
TW201613925A (en) | 2014-07-10 | 2016-04-16 | Incyte Corp | Imidazopyrazines as LSD1 inhibitors |
US9695168B2 (en) | 2014-07-10 | 2017-07-04 | Incyte Corporation | Substituted imidazo[1,5-α]pyridines and imidazo[1,5-α]pyrazines as LSD1 inhibitors |
US9695167B2 (en) | 2014-07-10 | 2017-07-04 | Incyte Corporation | Substituted triazolo[1,5-a]pyridines and triazolo[1,5-a]pyrazines as LSD1 inhibitors |
US9758523B2 (en) | 2014-07-10 | 2017-09-12 | Incyte Corporation | Triazolopyridines and triazolopyrazines as LSD1 inhibitors |
US9944647B2 (en) | 2015-04-03 | 2018-04-17 | Incyte Corporation | Heterocyclic compounds as LSD1 inhibitors |
JP7427363B2 (ja) | 2015-08-12 | 2024-02-05 | インサイト・ホールディングス・コーポレイション | Lsd1阻害剤の塩 |
TW201726140A (zh) | 2015-09-17 | 2017-08-01 | 瑞典商阿斯特捷利康公司 | 治療癌症之新型生物標記及方法 |
ES2963148T3 (es) | 2016-04-22 | 2024-03-25 | Incyte Corp | Formulaciones de un inhibidor de LSD1 |
WO2020047198A1 (en) | 2018-08-31 | 2020-03-05 | Incyte Corporation | Salts of an lsd1 inhibitor and processes for preparing the same |
CN114728003A (zh) | 2019-11-04 | 2022-07-08 | 阿斯利康(瑞典)有限公司 | 治疗b细胞恶性肿瘤的阿卡替尼和卡帕塞替尼的治疗组合 |
EP4271678A1 (en) * | 2021-01-04 | 2023-11-08 | Teva Pharmaceuticals International GmbH | Solid state forms of capivasertib and process for preparation thereof |
WO2023187037A1 (en) | 2022-03-31 | 2023-10-05 | Astrazeneca Ab | Epidermal growth factor receptor (egfr) tyrosine kinase inhibitors in combination with an akt inhibitor for the treatment of cancer |
CN114601836B (zh) * | 2022-04-12 | 2022-12-06 | 四川大学华西医院 | 一种akt抑制剂在制备治疗乳腺癌的药物中的应用 |
WO2024083716A1 (en) | 2022-10-17 | 2024-04-25 | Astrazeneca Ab | Combinations of a serd for the treatment of cancer |
WO2024100236A1 (en) | 2022-11-11 | 2024-05-16 | Astrazeneca Ab | Combination therapies for the treatment of cancer |
WO2024104561A1 (en) | 2022-11-15 | 2024-05-23 | Astrazeneca Ab | Therapeutic combinations of capivasertib and venetoclax |
Family Cites Families (70)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NL297170A (hr) | 1963-04-04 | 1900-01-01 | ||
GB9312853D0 (en) | 1993-06-22 | 1993-08-04 | Euro Celtique Sa | Chemical compounds |
GB9624482D0 (en) | 1995-12-18 | 1997-01-15 | Zeneca Phaema S A | Chemical compounds |
CZ291386B6 (cs) | 1996-02-13 | 2003-02-12 | Zeneca Limited | Chinazolinové deriváty jako inhibitory VEGF, způsob jejich přípravy a farmaceutický prostředek, který je obsahuje |
NZ331191A (en) | 1996-03-05 | 2000-03-27 | Zeneca Ltd | 4-anilinoquinazoline derivatives and pharmaceutical compositions thereof |
WO1997038665A2 (en) | 1996-04-03 | 1997-10-23 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
GB9718972D0 (en) | 1996-09-25 | 1997-11-12 | Zeneca Ltd | Chemical compounds |
DK0961780T3 (da) | 1997-02-12 | 2007-08-27 | Electrophoretics Ltd | Proteinmarkörer for lungecancer og anvendelse deraf |
US6432947B1 (en) | 1997-02-19 | 2002-08-13 | Berlex Laboratories, Inc. | N-heterocyclic derivatives as NOS inhibitors |
GB9714249D0 (en) | 1997-07-08 | 1997-09-10 | Angiogene Pharm Ltd | Vascular damaging agents |
IL133430A0 (en) | 1997-08-05 | 2001-04-30 | Pfizer Prod Inc | 4-AMINOPYRROLE (3, 2-d) PYRIMIDINES AS NEUROPEPTIDE Y RECEPTOR ANTAGONISTS |
US6162804A (en) | 1997-09-26 | 2000-12-19 | Merck & Co., Inc. | Tyrosine kinase inhibitors |
KR20010052570A (ko) | 1998-06-04 | 2001-06-25 | 스티븐 에프. 웨인스톡 | 세포 유착을 억제하는 소염성 화합물 |
PA8474101A1 (es) | 1998-06-19 | 2000-09-29 | Pfizer Prod Inc | Compuestos de pirrolo [2,3-d] pirimidina |
US6262066B1 (en) | 1998-07-27 | 2001-07-17 | Schering Corporation | High affinity ligands for nociceptin receptor ORL-1 |
GB9900334D0 (en) | 1999-01-07 | 1999-02-24 | Angiogene Pharm Ltd | Tricylic vascular damaging agents |
GB9900752D0 (en) | 1999-01-15 | 1999-03-03 | Angiogene Pharm Ltd | Benzimidazole vascular damaging agents |
US7074800B1 (en) | 1999-02-10 | 2006-07-11 | Astrazeneca Ab | Quinazoline derivatives as angiogenesis inhibitors |
WO2000075145A1 (en) | 1999-06-03 | 2000-12-14 | Abbott Laboratories | Cell adhesion-inhibiting antiinflammatory compounds |
CN101219145A (zh) | 1999-11-05 | 2008-07-16 | 阿斯特拉曾尼卡有限公司 | 作为vegf抑制剂的喹唑啉衍生物 |
US7160890B2 (en) | 1999-12-02 | 2007-01-09 | Osi Pharmaceuticals, Inc. | Compounds specific to adenosine A3 receptor and uses thereof |
DE122008000002I1 (de) | 2000-02-15 | 2008-04-17 | Sugen Inc | Pyrrol substituierte indolin-2-on protein kinase inhibitoren |
MXPA02011770A (es) | 2000-05-31 | 2003-04-10 | Astrazeneca Ab | Derivados de indol con actividad de dano vascular. |
UA73993C2 (uk) | 2000-06-06 | 2005-10-17 | Астразенека Аб | Хіназолінові похідні для лікування пухлин та фармацевтична композиція |
PL359563A1 (en) | 2000-06-26 | 2004-08-23 | Pfizer Products Inc. | Pyrrolo[2,3-d]pyrimidine compounds as immunosuppressive agents |
AU2001266232B2 (en) | 2000-07-07 | 2005-09-15 | Angiogene Pharmaceuticals Limited | Colchinol derivatives as angiogenesis inhibitors |
CN1255391C (zh) | 2000-07-07 | 2006-05-10 | 安吉奥金尼药品有限公司 | 作为血管破坏剂的colchinol衍生物 |
WO2002018348A2 (en) | 2000-08-31 | 2002-03-07 | F. Hoffman-La Roche Ag | Quinazoline derivatives as alpha-1 adrenergic antagonists |
PL363245A1 (en) | 2000-12-01 | 2004-11-15 | Osi Pharmaceuticals, Inc. | Compounds specific to adenosine a1 |
US6680324B2 (en) | 2000-12-01 | 2004-01-20 | Osi Pharmaceuticals, Inc. | Compounds specific to adenosine A1 receptors and uses thereof |
US6673802B2 (en) | 2000-12-01 | 2004-01-06 | Osi Pharmaceuticals, Inc. | Compounds specific to adenosine A3 receptor and uses thereof |
CA2445568A1 (en) * | 2001-04-27 | 2002-11-07 | Vertex Pharmaceuticals Incorporated | Triazole-derived kinase inhibitors and uses thereof |
EP1707566A1 (en) | 2002-01-07 | 2006-10-04 | Eisai Co., Ltd. | Deazapurines and uses thereof |
TW200403058A (en) | 2002-04-19 | 2004-03-01 | Bristol Myers Squibb Co | Heterocyclo inhibitors of potassium channel function |
DK1522314T3 (da) | 2002-06-26 | 2014-05-26 | Ono Pharmaceutical Co | Midler for sygdomme forårsaget af vaskulær sammentrækning eller udvidelse |
US20040138238A1 (en) | 2002-08-08 | 2004-07-15 | Dhanoa Dale S. | Substituted aminopyrimidine compounds as neurokinin antagonists |
US20030139427A1 (en) | 2002-08-23 | 2003-07-24 | Osi Pharmaceuticals Inc. | Bicyclic pyrimidinyl derivatives and methods of use thereof |
US20050288503A1 (en) | 2002-09-06 | 2005-12-29 | Adams Jerry L | Novel compounds |
EP1567495A4 (en) | 2002-11-08 | 2007-10-31 | Harvard College | SMALL, WITH TECHNETIUM-99M AND RHENIUM-MARKED MEDIUM AND METHOD OF ILLUMINATING WOVEN FABRICS, ORGANS AND TUMORS |
RU2328498C9 (ru) | 2002-12-04 | 2008-12-10 | Эйсай Ар Энд Ди Менеджмент Ко., Лтд. | Соединения с конденсированным 1,3-дигидроимидазольным циклом |
EP1444982A1 (de) | 2003-02-06 | 2004-08-11 | Merckle Gmbh | Verwendung von Purinderivaten als selektive Kinase-Inhibitoren |
JP2006519846A (ja) | 2003-03-10 | 2006-08-31 | シェーリング コーポレイション | 複素環式キナーゼインヒビター:使用および合成の方法 |
EP1615926A1 (en) | 2003-04-21 | 2006-01-18 | Ustav Organicke Chemie A Biochemie Akademie Ved Ceske Republiky | (purin-6-yl) amino acid and production method thereof |
FR2856685B1 (fr) | 2003-06-25 | 2005-09-23 | Merck Sante Sas | Derives de thiazolylpiperidine, leurs procedes de preparation et les compositions pharmaceutiques qui les contiennent |
AU2004268621C1 (en) | 2003-08-29 | 2011-08-18 | Exelixis, Inc. | c-Kit modulators and methods of use |
WO2005044181A2 (en) | 2003-09-09 | 2005-05-19 | Temple University-Of The Commonwealth System Of Higher Education | Protection of tissues and cells from cytotoxic effects of ionizing radiation by abl inhibitors |
TW200526626A (en) | 2003-09-13 | 2005-08-16 | Astrazeneca Ab | Chemical compounds |
RU2006121990A (ru) | 2003-11-21 | 2007-12-27 | Эррэй Биофарма Инк. (Us) | Ингибиторы протеинкиназ акт |
EP1698375B1 (en) | 2003-12-25 | 2014-04-02 | Ono Pharmaceutical Co., Ltd. | Azetidine ring compounds and drugs comprising the same |
RU2006138036A (ru) * | 2004-03-30 | 2008-05-10 | Чирон Корпорейшн (Us) | Производные замещенного тиофена в качестве противораковых средств |
EP1750727A2 (en) * | 2004-04-23 | 2007-02-14 | Exelixis, Inc. | Kinase modulators and methods of use |
MY179032A (en) * | 2004-10-25 | 2020-10-26 | Cancer Research Tech Ltd | Ortho-condensed pyridine and pyrimidine derivatives (e.g.purines) as protein kinase inhibitors |
UY29177A1 (es) * | 2004-10-25 | 2006-05-31 | Astex Therapeutics Ltd | Derivados sustituidos de purina, purinona y deazapurina, composiciones que los contienen métodos para su preparación y sus usos |
CA2590961C (en) * | 2004-12-28 | 2013-11-26 | Exelixis, Inc. | [1h-pyrazolo[3,4-d]pyrimidin-4-yl]-piperidine or -piperazine compounds as serine-threonine kinase modulators (p70s6k, atk1 and atk2) for the treatment of immunological, inflammatory and proliferative diseases |
FR2880626B1 (fr) | 2005-01-13 | 2008-04-18 | Aventis Pharma Sa | Derives de la purine, compositions les contenant et utilisation |
FR2880540B1 (fr) | 2005-01-13 | 2008-07-11 | Aventis Pharma Sa | Utilisation de derives de la purine comme inhibiteurs de la proteine hsp90 |
US7423043B2 (en) | 2005-02-18 | 2008-09-09 | Lexicon Pharmaceuticals, Inc. | 4-Piperidin-1-yl-7H-pyrrolo[2,3-d]pyrimidine compounds |
US20060281768A1 (en) | 2005-06-10 | 2006-12-14 | Gaul Michael D | Thienopyrimidine and thienopyridine kinase modulators |
WO2007007919A2 (en) | 2005-07-14 | 2007-01-18 | Astellas Pharma Inc. | Heterocyclic janus kinase 3 inhibitors |
US20070049591A1 (en) | 2005-08-25 | 2007-03-01 | Kalypsys, Inc. | Inhibitors of MAPK/Erk Kinase |
EP1979353A2 (en) | 2006-01-19 | 2008-10-15 | OSI Pharmaceuticals, Inc. | Fused heterobicyclic kinase inhibitors |
US20100016340A1 (en) | 2006-04-25 | 2010-01-21 | Astex Therapeutics Limited | Pharmaceutical compounds |
JP5606734B2 (ja) | 2006-04-25 | 2014-10-15 | アステックス、セラピューティックス、リミテッド | 医薬化合物 |
US20090124610A1 (en) | 2006-04-25 | 2009-05-14 | Gordon Saxty | Pharmaceutical compounds |
WO2007125315A2 (en) | 2006-04-25 | 2007-11-08 | Astex Therapeutics Limited | Pharmaceutical compounds |
WO2007125310A2 (en) | 2006-04-25 | 2007-11-08 | Astex Therapeutics Limited | Pharmaceutical combinations of pk inhibitors and other active agents |
AR064415A1 (es) | 2006-12-21 | 2009-04-01 | Cancer Rec Tech Ltd | Derivados de pirrolo-piperidinas y purinas,composiciones farmaceuticas que los contienen y usos en trastornos y/o enfermedades mediadas por pka y pkb. |
KR20090091350A (ko) | 2006-12-21 | 2009-08-27 | 버텍스 파마슈티칼스 인코포레이티드 | 단백질 키나제 억제제로 유용한 5-시아노-4-피롤로[2,3b]피리딘-3-일)-피리디민 유도체 |
AR064416A1 (es) | 2006-12-21 | 2009-04-01 | Cancer Rec Tech Ltd | Derivados de purina, piridina y pirimidina condensadas con heterociclos, moduladores de pka y/o pkb, composiciones farmaceuticas que los contienen, y usos para el tratamiento de enfermedades hiperproliferativas. |
ES2522365T3 (es) | 2007-10-11 | 2014-11-14 | Astrazeneca Ab | Derivados de pirrolo [2,3-D] pirimidina como inhibidores de proteína quinasas B |
-
2008
- 2008-10-09 ES ES08806741.8T patent/ES2522365T3/es active Active
- 2008-10-09 CA CA2701057A patent/CA2701057C/en active Active
- 2008-10-09 MX MX2010003927A patent/MX2010003927A/es active IP Right Grant
- 2008-10-09 WO PCT/GB2008/050925 patent/WO2009047563A1/en active Application Filing
- 2008-10-09 MY MYPI2010001617A patent/MY150059A/en unknown
- 2008-10-09 DK DK08806741.8T patent/DK2201012T3/da active
- 2008-10-09 AU AU2008309383A patent/AU2008309383B2/en active Active
- 2008-10-09 NZ NZ585261A patent/NZ585261A/en unknown
- 2008-10-09 CN CN200880116651XA patent/CN101861321B/zh active Active
- 2008-10-09 PL PL08806741T patent/PL2201012T3/pl unknown
- 2008-10-09 BR BRPI0818533A patent/BRPI0818533B8/pt active IP Right Grant
- 2008-10-09 EA EA201000552A patent/EA018512B1/ru not_active IP Right Cessation
- 2008-10-09 UY UY31384A patent/UY31384A1/es not_active Application Discontinuation
- 2008-10-09 EP EP08806741.8A patent/EP2201012B1/en active Active
- 2008-10-09 SI SI200831281T patent/SI2201012T1/sl unknown
- 2008-10-09 PT PT88067418T patent/PT2201012E/pt unknown
- 2008-10-09 TW TW097139021A patent/TWI453021B/zh active
- 2008-10-09 KR KR1020107010107A patent/KR101494734B1/ko active IP Right Grant
- 2008-10-09 RS RS20140457A patent/RS53552B1/en unknown
- 2008-10-09 JP JP2010528485A patent/JP4705695B2/ja active Active
- 2008-10-09 ME MEP-2014-102A patent/ME01999B/me unknown
- 2008-10-10 US US12/249,477 patent/US8101623B2/en active Active
- 2008-10-10 AR ARP080104450A patent/AR068846A1/es active IP Right Grant
- 2008-10-10 CL CL2008003023A patent/CL2008003023A1/es unknown
- 2008-10-10 PE PE2012002041A patent/PE20130152A1/es not_active Application Discontinuation
- 2008-10-10 PE PE2008001748A patent/PE20090964A1/es active IP Right Grant
- 2008-10-11 SA SA8290625A patent/SA08290625B1/ar unknown
-
2010
- 2010-03-25 IL IL204721A patent/IL204721A/en active IP Right Grant
- 2010-03-31 ZA ZA2010/02318A patent/ZA201002318B/en unknown
- 2010-04-09 GT GT201000082A patent/GT201000082A/es unknown
- 2010-04-09 DO DO2010000103A patent/DOP2010000103A/es unknown
- 2010-04-09 HN HN2010000653A patent/HN2010000653A/es unknown
- 2010-04-09 CU CU20100062A patent/CU23886B1/es active IP Right Grant
- 2010-04-09 NI NI201000050A patent/NI201000050A/es unknown
- 2010-04-09 CR CR11359A patent/CR11359A/es unknown
- 2010-05-06 CO CO10054272A patent/CO6270328A2/es active IP Right Grant
- 2010-10-12 HK HK10109649.4A patent/HK1143154A1/xx unknown
-
2011
- 2011-03-09 JP JP2011051117A patent/JP5330430B2/ja active Active
- 2011-12-13 US US13/324,191 patent/US20120190679A1/en not_active Abandoned
-
2014
- 2014-08-26 HR HRP20140807AT patent/HRP20140807T1/hr unknown
- 2014-08-28 CY CY20141100689T patent/CY1116929T1/el unknown
-
2015
- 2015-02-19 US US14/626,303 patent/US9492453B2/en active Active
-
2016
- 2016-11-15 US US15/351,481 patent/US10059714B2/en active Active
-
2018
- 2018-07-06 US US16/028,979 patent/US10654855B2/en active Active
-
2020
- 2020-04-07 US US16/841,820 patent/US11236095B2/en active Active
-
2021
- 2021-12-16 US US17/644,654 patent/US11760760B2/en active Active
-
2023
- 2023-08-04 US US18/365,286 patent/US20240109902A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20140807T1 (hr) | Derivati pirolo[2,3-d]pirimidina kao inhibitori protein kinaze b | |
AU2020213313B2 (en) | Treatment of b-cell malignancies by a combination jak and pi3k inhibitor | |
JP7000333B2 (ja) | メニン-mllの架橋された二環式阻害剤及びその使用方法 | |
ES2665539T3 (es) | Derivados de benzamida para inhibir la actividad de ABL1, ABL2 y BCR-ABL1 | |
UA121104C2 (uk) | Гетероциклічні сполуки і їх застосування | |
CA3048340A1 (en) | Pharmaceutical combination comprising an alk inhibitor and a shp2 inhibitor | |
WO2017007701A1 (en) | Antiviral phosphodiamide compounds | |
WO2007065664A3 (en) | Pyrazolo[1,5-a]pyridine-3-carboxylic acids as ephb and vegfr2 kinase inhibitors | |
WO2014130856A2 (en) | Treatment of skeletal-related disorders | |
MX2023000782A (es) | 7-bencil-4-(2-metilbencilo)-2,4,6,7,8,9-hexahidroimidazo [1,2-a]pirido[3,4-e]pirimidin-5(1h)-ona, analogos y sales del mismo y su uso en terapia. | |
TW200730502A (en) | Isoquinoline aminopyrazole derivatives, their manufacture and use as pharmaceutical agents | |
EA201070841A1 (ru) | НОВЫЕ ПИРАЗОЛО[3,4-d]ПИРИМИДИНОВЫЕ ПРОИЗВОДНЫЕ В КАЧЕСТВЕ ПРОТИВОРАКОВЫХ ЛЕКАРСТВЕННЫХ СРЕДСТВ | |
WO2006067445A3 (en) | Csf-1r kinase inhibitors | |
MX2010006748A (es) | Pirazolo[1,5-a]pirimidinas utiles como inhibidores de jak2. | |
RU2016141569A (ru) | Комбинации | |
WO2008070313A3 (en) | 3-(dihydro-1h-pyrazolo [4,3-d] pyrimidin-5-yl)-4-propoxybenzenesulfonamide derivatives and methods of use | |
EA201290878A1 (ru) | ПРОИЗВОДНЫЕ ИМИДАЗО[1,2-a]ПИРАЗИНА И ИХ ПРИМЕНЕНИЕ ДЛЯ ПРОФИЛАКТИКИ ИЛИ ЛЕЧЕНИЯ НЕВРОЛОГИЧЕСКИХ, ПСИХИАТРИЧЕСКИХ И МЕТАБОЛИЧЕСКИХ РАССТРОЙСТВ И ЗАБОЛЕВАНИЙ | |
IL292229A (en) | Pharmacological combination of prmt5 inhibitors | |
WO2008068507A3 (en) | 2 -phenylamino, 6- (pyrid-3-yl) quinazoline derivatives as raf-protein kinase inhibitors in cancer treatment | |
UA106225C2 (ru) | СОЛИ ПРОИЗВОДНЫХ ТЕТРАГИДРОИМИДАЗО[1,5-а]ПИРАЗИНА, СПОСОБ ПОЛУЧЕНИЯ (ВАРИАНТЫ) И ИХ МЕДИЦИНСКОЕ ПРИМЕНЕНИЕ | |
WO2020051572A1 (en) | Brd4-jak2 inhibitors | |
EA200800920A1 (ru) | Производные пиразоло[4,3-d]пиримидин-5-ила, применяемые в качестве ингибиторов фосфодиэстеразы 5 (pde5) | |
PH12020552236A1 (en) | Crystal form of compound for inhibiting the activity of cdk4/6 and use thereof | |
KR20240035837A (ko) | 약화된 이미드 활성을 지닌 btk를 분해하기 위한 이작용성 화합물 | |
JP2018511627A5 (hr) |